Genomic Test Safely Guides Breast Cancer Chemotherapy Exemption, Trial Finds

The Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (OPTIMA) trial, a major international clinical study, evaluated 4,429 participants aged 40 or older to assess the efficacy of gene-directed care.

Led by University College London (UCL), the study tracked patients across the United Kingdom, Norway, Sweden, Australia, New Zealand, and Thailand.

The investigation focused on patients diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, which represents the most prevalent form of the disease globally.

Researchers utilized a specific genomic expression assay known as the Prosigna test to measure the activity of 50 distinct genes within excised tumor tissue.

The diagnostic tool assigns a risk score based on the underlying molecular biology of the tumor, classifying the disease as low, intermediate, or high risk for future recurrence.

In the randomized trial, patients in the test-directed group who presented with low risk scores skipped conventional chemotherapy entirely, receiving hormone therapy alone.

Five years after treatment, the survival outcomes between the two primary comparative arms of the study remained exceptionally narrow.

Among patients who received standard chemotherapy combined with hormone therapy, 94.8% were alive and free from breast cancer recurrence.

For the group assigned to skip chemotherapy based on low genomic test results, 93.6% remained alive and free of recurrence.

The 1.2% difference fell well within the strict, pre-defined 3% non-inferiority margin established by the research team, clinicians, and patient panels before the trial.

Statistical analysis demonstrated that chemotherapy provided a meaningful benefit to at most 2% of the patients identified with low-risk gene profiles.

The finding suggests that the treatment offers little to no clinical advantage for a significant subset of patients, while exposing them to severe systemic toxicities.

Bypassing cytotoxic drugs spares individuals from substantial physical and psychological burdens, including hair loss, prolonged fatigue, cognitive difficulties, and permanent risks like infertility or cardiac complications.

The trial also demonstrated that the predictive accuracy of the 50-gene signature remained consistent across distinct patient demographics.

The outcomes did not differ significantly between pre-menopausal and post-menopausal women.

Furthermore, the genomic test remained reliable regardless of the number of affected lymph nodes, even in cases where the cancer had spread to more than three nodes.

By basing treatment paths on precise tumor biology rather than traditional clinical markers like tumor size, health systems can allocate resources more efficiently.

Investigators estimate that the widespread integration of this testing protocol could allow more than 5,000 patients annually within the National Health Service (NHS) to bypass unnecessary chemotherapy.

On a broader scale, precision oncology testing could alter standard care guidelines globally, potentially preventing millions of women from undergoing unnecessary cytotoxic treatments.